Cover Image
市場調查報告書

BioCryst Pharmaceuticals, Inc. - 產品產品管道分析

BioCryst Pharmaceuticals, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 226252
出版日期 內容資訊 英文 37 Pages
訂單完成後即時交付
價格
Back to Top
BioCryst Pharmaceuticals, Inc. - 產品產品管道分析 BioCryst Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日期: 2015年05月29日 內容資訊: 英文 37 Pages
簡介

BioCryst Pharmaceuticals, Inc.是開發酵素小分子藥劑、活用、新藥開發的生技企業。針對發炎性病患與遺傳性血管浮腫治療藥開發。透過架構藥物設計等方法、結合各種醫療分類知識與技術開發小分子藥劑。

本報告針對BioCryst Pharmaceuticals, Inc. 治療藥開發管道現況與各開發階段比較分析、藥劑標的、作用機序、用藥管道、分子種類分類治療藥評價、最新企業新聞與發表、後期階段以及中止計畫相關情報。

BioCryst Pharmaceuticals, Inc.基本情報

BioCryst Pharmaceuticals, Inc.概要

  • 主要情報
  • 企業情報

BioCryst Pharmaceuticals, Inc.:R&D概要

  • 主要治療範圍

BioCryst Pharmaceuticals, Inc.:產品管道回顧

  • 開發階段分類產品管道產品
  • 單劑產品
  • 對外授權產品
    • 對外授權產品/併用療法模式

BioCryst Pharmaceuticals, Inc.:產品管道產品概況

  • 最終階段產品管道產品
    • 登錄前產品/併用療法模式
  • 治療階段產品管道產品
    • 第II期產品/併用療法模式
  • 初期階段產品管道產品
    • 前臨床階段產品/併用療法模式

BioCryst Pharmaceuticals, Inc.:藥劑檔案

  • peramivir
  • BCX-4161
  • ulodesine
  • BCX-4430
  • Second Generation Plasma Kallikrein Inhibitor 1

BioCryst Pharmaceuticals, Inc.:產品管道分析

  • 標的分類
  • 用藥管道分類
  • 分子種類分類
  • 作用機序分類

BioCryst Pharmaceuticals, Inc.:最近產品管道動向

BioCryst Pharmaceuticals, Inc.:暫停計畫

BioCryst Pharmaceuticals, Inc.:開發中止產品管道產品

  • 開發中止產品管道產品檔案
    • BCX-5191
    • peldesine

BioCryst Pharmaceuticals, Inc.:企業發表

BioCryst Pharmaceuticals, Inc.:總公司與子公司所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07102CDB

Summary

Global Markets Direct's, 'BioCryst Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the BioCryst Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of BioCryst Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of BioCryst Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of BioCryst Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the BioCryst Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate BioCryst Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of BioCryst Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the BioCryst Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of BioCryst Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of BioCryst Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of BioCryst Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • BioCryst Pharmaceuticals, Inc. Snapshot
    • BioCryst Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • BioCryst Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • BioCryst Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • BioCryst Pharmaceuticals, Inc. - Pipeline Products Glance
    • BioCryst Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • BioCryst Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • BioCryst Pharmaceuticals, Inc. - Drug Profiles
    • BCX-4161
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BCX-4430
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BCX-7353
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 2 to Inhibit Plasma Kallikrein for Hereditary Angioedema
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BCX-xxxx
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • BioCryst Pharmaceuticals, Inc. - Pipeline Analysis
    • BioCryst Pharmaceuticals, Inc. - Pipeline Products by Target
    • BioCryst Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • BioCryst Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • BioCryst Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • BioCryst Pharmaceuticals, Inc. - Recent Pipeline Updates
  • BioCryst Pharmaceuticals, Inc. - Dormant Projects
  • BioCryst Pharmaceuticals, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • BCX-5191
      • peldesine
  • BioCryst Pharmaceuticals, Inc. - Company Statement
  • BioCryst Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • BioCryst Pharmaceuticals, Inc., Key Information
  • BioCryst Pharmaceuticals, Inc., Key Facts
  • BioCryst Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • BioCryst Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • BioCryst Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • BioCryst Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2015
  • BioCryst Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • BioCryst Pharmaceuticals, Inc. - Phase II, 2015
  • BioCryst Pharmaceuticals, Inc. - Phase I, 2015
  • BioCryst Pharmaceuticals, Inc. - Preclinical, 2015
  • BioCryst Pharmaceuticals, Inc. - Discovery, 2015
  • BioCryst Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • BioCryst Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • BioCryst Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • BioCryst Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
  • BioCryst Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015
  • BioCryst Pharmaceuticals, Inc. - Dormant Developmental Projects,2015
  • BioCryst Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2015
  • BioCryst Pharmaceuticals, Inc., Other Locations
  • BioCryst Pharmaceuticals, Inc., Subsidiaries

List of Figures

  • BioCryst Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • BioCryst Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • BioCryst Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • BioCryst Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • BioCryst Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • BioCryst Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • BioCryst Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top